25 / 76
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 6, November/December 2016
AFRICA
355
carditis.
Surg Today
2004;
34
: 569–572.
11. Juneja R, Kothari SS, Saxena A,
et al
. Intrapericardial streptokinase in
purulent pericarditis.
Arch Dis Child
1999;
80
: 275–277.
12. Graham W, Roberts JB. Intravenous colchicine in the treatment of
gouty arthritis.
Ann Rheum Dis
1953;
12
(1): 16–19.
13. Imazio M, Bobbio M, Cecchi E, Demarie D, Demichelis B, Pomari F,
et
al
. Colchicine in addition to conventional therapy for acute pericarditis –
results of the Colchicine for Acute Pericarditis (COPE) trial.
Circulation
2005;
112
: 2012–2016.
14. Guidelines: National Tuberculosis Management Guidelines. Health-e.
2015 [online] Available at:
http://www.health-e.org.za/2014/06/10/guide-lines-national-tuberculosis-manangement-guidelines/. [Accessed 23
August 2015].
15. Reuter H, Burgess L, van Vuuren W, Doubell A. Diagnosing tubercu-
lous pericarditis.
Q J Med
2006;
99
(12): 827–839.
16. Dal-Bianco JP, Sengupta PP, Mookadam F, Chandrasekaran K, Tajik
AJ, Khandheria BK. Role of echocardiography in the diagnosis of
constricitve pericarditis.
J Am Soc Echocardiogr
2009;
22
(1): 24–33.
17. BSE: A standard transthoracic echo. 2015. [online] Available at: http://
www.bsecho.org/tte-minimum-dataset/[Accessed 23 August 2015].
18. Oh JK, Tajik JT, Christopher PA, Hatle LK, Nishimura RA, Seward
JB. Preload reduction to unmask the characteristic Doppler features of
constrictive pericarditis.
Circulation
1997;
95
: 796–799.
19. Boonyaratavej S, Oh JK, Tajik AJ, Appleton CP, Seward JB. Comparison
of mitral inflow and superior vena cava Doppler velocities in chronic
obstructive pulmonary disease and constrictive pericarditis.
J Am
Cardiol
1989;
63
: 483–488.
Confidence Through Clinical
and Real World Experience
1-3
Millions of Patients Treated Across Multiple Indications
4
#1 NOAC prescribed by Cardiologists
*
References:
1.
Patel M.R., Mahaffey K.W., Garg J.
et al.
Rivaroxaban versus warfarin in non-valvular atrial fibrillation.
N Engl J Med
. 2011;365(10):883–91.
2.
Tamayo S., Peacock W.F., Patel M.R.,
et al.
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
. 2015;38(2):63–8.
3.
Camm A.J., Amarenco P., Haas S.
et al.
XANTUS: A Real-World,
Prospective, Observational Study.
4.
Calculation based on IMS Health MIDAS, Database: Monthly Sales December 2015.
For fullprescribing information,refer to thepackage insertapprovedby theMedicinesRegulatoryAuthority (MCC). S4 XARELTO
®
10 (Film-coated tablets)
.Reg.No.:42/8.2/1046.Eachfilm-coated tabletcontainsrivaroxaban10mg.
PHARMACOLOGICALCLASSIFICATION:
A.8.2Anticoagulants.
INDICATION:
Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. S4 XARELTO
®
15 and XARELTO
®
20 (Film-coated tablets). Reg. No.: XARELTO
®
15: 46/8.2/0111; XARELTO
®
20: 46/8.2/0112. Each film
coated tablet contains rivaroxaban 15 mg (XARELTO
®
15) or 20 mg (XARELTO
®
20).
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATIONS:
(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2)
Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).
HCR:
Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.
L.ZA.MKT.GM.01.2016.1265
*Impact RX Data Oct - Dec 2015
NOAC: Non Vitamin K Oral Anticoagulant